XZO · Investment summary · as of 4 August 2026
Priced slightly ahead of what the business has demonstrated
Business type: Compounder · scaling but economically observable
The evidence needed to judge business quality is not established, so the underwriting supports no position.
At $15.98, XZO requires a 11% five-year revenue growth rate to justify its enterprise value — more than the business has ever demonstrated, at 9%.
The disagreement is entirely about whether revenue re-converges on managed-premium growth (take-rate compression stops) or continues to lag it. The terminal margin is not in dispute — 44.5% sits 0.65pp below the most recent printed quarter.
The value rests on an exit multiple of 7.2x, a terminal operating margin of 44% and a 13.3% cost of capital. Move any one of them materially and the conclusion moves with it, which is why the required-versus-demonstrated test above carries more weight here than the point value.
The strongest argument against this view: HCI resets the take rate.
| Question | Evidence-based conclusion |
|---|---|
| What drives the business? | The disagreement is entirely about whether revenue re-converges on managed-premium growth (take-rate compression stops) or continues to lag it. |
| What do we forecast? | Revenue growth of 9% demonstrated; a terminal operating margin of 44%; an exit multiple of 7.2x. |
| What does Street forecast? | Not determined — no consensus estimates are joined to this record |
| Where do we differ? | On revenue growth, the difference between what the price requires and what the business has demonstrated is -2.4 percentage points. |
| What is it worth? | Twelve-month target $16.87, +6% from the struck price. Scenario-weighted expected return net of costs +5.6%. |
| Why now? | Date not announced — no dated event that would resolve the disagreement is on file |
| Date or window | Event | Thesis confirmed if | Thesis weakened or refuted if |
|---|---|---|---|
| each 10-Q | Managed premium growth YoY | Neither leg of the condition opposite is met at this date | managed premium growth YoY below +8.0% in two consecutive quarters (currently +14.85% (Q1-2026)) |
| each 10-Q | ARR | ARR at or above $210.0m in any quarter (currently $216.2m (Q1-2026)) | ARR below $210.0m in any quarter (currently $216.2m (Q1-2026)) |
| each 10-Q | Realised annualised take rate (revenue / period-end managed premium x… | Realised annualised take rate (revenue / period-end managed premium x 4) at or above 14.5% in two consecutive quarters… | realised annualised take rate (revenue / period-end managed premium x 4) below 14.5% in two consecutive quarters… |
| each 10-Q | Quarterly revenue | Quarterly revenue at or above $52.0m (beneath the five-quarter band floor) in any quarter (currently $55.5m (Q1-2026)) | quarterly revenue below $52.0m (beneath the five-quarter band floor) in any quarter (currently $55.5m (Q1-2026)) |
HCI resets the take rate. HCI owns 82.5% of XZO and is the counterparty to 98.9%+ of its revenue, so it retains 82.5% of any margin moved from XZO to an HCI carrier — the incentive to under-price the intercompany MGA and technology agreements is structural and permanent, not a tail risk, and the agreements are terminable on notice. The compression has ALREADY begun: the realised annualised take rate fell 16.85% -> 15.54% (-130bp) in the year to Q1-2026, which is the entire reason revenue grew +6.0% while managed premium grew +14.9%. A one-third reset, with cost of revenue held fixed because policy count is unchanged, gives EBIT $33.9m and $6.23/share — a 61.0% permanent loss. Threshold = 0.10/0.610 = 16.4%; at a stated 17.5% probability over 3 years the impairment rung FIRES.
Estimated probability 18%, against the 16% level at which the position would be resized. It sits above that level, so this case could not be carried at full size.
Falsifiable and fundamental — not one of them is a price condition.
On approach to the $16.87 target the case is reviewed rather than added to; a target reached is a reason to re-examine the position, not to hold it by default. The position is trimmed once forward expected return falls below 0% net of costs, because the capital has a better use elsewhere in the book.
| Criteria | Status | Investment meaning |
|---|---|---|
| Quality | Not determined | Is the business worth owning under its declared economic type? Not established on the evidence on file. |
| Valuation | Not met | Is the operating path required by today's price achievable? |
| Liquidity | Met | Can the intended position be built and exited in the right vehicle? |
| Downside | Met | HCI resets the take rate. |
| Momentum | Not determined | Does price action support or complicate entry timing? Not established on the evidence on file. |
| Catalyst | Not determined | Is there a dated event that resolves the disagreement? Not established on the evidence on file. |
| Consensus | Not determined | Is the house-versus-Street disagreement identified and quantified? Not established on the evidence on file. |
Quality, valuation and liquidity can prevent a position on their own. The remaining four inform timing, sizing and monitoring, and never reject an investment by themselves.
The gap between what today's price requires and what the business has demonstrated is -2.4 percentage points, and that gap — not the multiple — is the case that the security is mispriced. The most important unresolved uncertainty is whether this is a business worth owning at all — the evidence for its quality is not established. The next evidence that should change the portfolio decision is the next scheduled results, or a daily close below $13.46, which forces an immediate review.